A dedicated PET/CT imaging platform for radionuclide drug conjugates (RDCs) enables non‑invasive visualization of tracer biodistribution, target engagement, and off‑organ accumulation. Alfa Cytology provides comprehensive, one-stop PET/CT imaging services tailored to the specific pharmacokinetic profiles of novel radiopharmaceuticals. By combining state-of-the-art instrumentation with customized longitudinal study designs, the complexities of isotope half-life, chelator stability, and target affinity are addressed to ensure robust preclinical validation and accelerated pipeline progression.
Positron emission tomography (PET) combined with X‑ray computed tomography (CT) provides both functional and anatomical information in a single session. In preclinical RDC research, PET/CT tracks the real‑time distribution of positron‑emitting radiolabels in living rodents or larger animal models. This hybrid modality links radiochemical signal to precise anatomical localization, making it indispensable for evaluating tumor targeting, off‑target retention, and normal organ clearance of novel RDC constructs.
Fig.1 Routine PET imaging in neuro-oncologic practice. (Bolcaen, J., et al., 2021)
The core of PET imaging relies on the detection of coincident gamma rays produced by positron-electron annihilation events following the decay of a positron-emitting isotope (18F, 68Ga, 89Zr, etc.) conjugated to a targeting moiety. These events are reconstructed into three-dimensional tomographic images that reflect tracer concentration over time. Concurrently, X-ray-based CT imaging captures physical density variations across tissues, allowing for precise attenuation correction of the PET data and high-fidelity spatial normalization.
Compared to planar scintigraphy or single‑photon emission CT (SPECT), PET/CT offers superior sensitivity, spatial resolution, and absolute quantification capability. These features enable detection of low‑abundance RDCs, precise measurement of tumor uptake, and longitudinal monitoring of therapeutic candidates with minimal animal numbers.
Quantitative Accuracy
Standardized uptake values (SUV) and kinetic modeling provide true radiotracer concentration data, enabling direct comparisons across different animals, time points, and studies. PET/CT delivers absolute measures such as SUVmean, SUVmax, and %ID/g, which are essential for dose‑response assessments and translational scaling.
Longitudinal Monitoring
Allows for repeat imaging of the same subject, reducing animal cohort size and improving statistical power. By allowing each animal to serve as its own internal control, this approach minimizes the impact of biological variability when tracking RDC uptake, retention, or washout over extended periods, a capability that is particularly essential for assessing therapeutic efficacy.
High Sensitivity
The ability to detect picomolar concentrations of radiolabeled tracers far exceeds the limits of traditional optical imaging modalities. This extreme sensitivity permits the use of "tracer-level" doses that remain well below pharmacological thresholds, thereby preserving the native RDC behavior and avoiding the receptor saturation or off-target effects often induced by higher mass doses.
Anatomical Coregistration
Provides exact spatial localization of tracers within necrotic tumor cores, metastatic lesions, or clearance organs. The high‑resolution CT component maps PET signals to specific anatomical structures, such as tumor rim versus hypoxic center, or renal cortex versus medulla, enabling precise region‑of‑interest definition and eliminating ambiguity from standalone functional imaging.
Leveraging specialized expertise in radiochemistry, imaging physics, and RDC biology, a comprehensive suite of PET/CT services covers every need—from single‑time‑point biodistribution studies to dynamic pharmacokinetic scans. Alfa Cytology's services include custom radiolabeling of RDCs, protocol optimization, image reconstruction, and quantitative region‑of‑interest (ROI) analysis. The integration of automated image reconstruction and expert-led analysis ensures that every RDC candidate is evaluated with maximum scientific rigor, facilitating a deeper understanding of target engagement and off-target sequestration.
A broad range of positron‑emitting isotopes can be accommodated, each with distinct half‑lives and decay characteristics suited to different RDC scaffolds and biological questions. The imaging platform and reconstruction algorithms are optimized for each isotope's positron energy and branching ratio, ensuring accurate quantification across all tracers.
| Isotope | Half‑life | Typical Applications |
|---|---|---|
| ¹⁸F | 109.8 min | Small molecules, peptides, and glucose metabolism (FDG). |
| ⁶⁴Cu | 12.7 h | Proteins, fragments, and nanoparticles; dual PET/therapy potential. |
| ⁶⁸Ga | 67.7 min | PSMA-targeting agents and somatostatin analogs. |
| ⁸⁹Zr | 78.4 h | Immuno-PET; longitudinal tracking of monoclonal antibodies. |
| ¹²⁴I | 4.2 d | Long-term thyroid or antibody-based imaging studies. |
| … | … | … |
Biodistribution and Pharmacokinetic (PK) Profiling
Quantitative assessment of whole-body tracer distribution over defined intervals, calculating %ID/g in all major organs and tumors. Dynamic scanning further characterizes blood clearance, organ residence time, and excretion pathways to construct comprehensive PK profiles for RDC candidates.
Tumor Targeting and Receptor Occupancy Studies
High-resolution mapping of RDC accumulation within xenograft or PDX models to evaluate targeting efficiency. Specialized blocking studies using excess non‑labeled compounds or competitor ligands confirm binding specificity and allow semi‑quantitative estimation of receptor occupancy.
Dynamic PET Imaging for Kinetic Modeling
Continuous data acquisition enables complex compartmental modeling to differentiate free, non-specific, and bound tracer fractions. By deriving rate constants (K1, k2, ki), this service quantifies the underlying biological mechanisms of tracer uptake and retention within the tumor microenvironment.
Longitudinal Efficacy and Response Monitoring
Serial imaging is performed on the same subject to track changes in tumor volume, uptake intensity, and target expression over time. This longitudinal design significantly reduces inter-animal variability, providing more robust and statistically powerful estimates of therapeutic effect.
Internal Dosimetry and Safety Estimation
Calculation of time‑integrated activity (residence times) from serial PET/CT datasets to determine absorbed radiation doses in target and non‑target tissues. These findings provide the essential foundational data required for human dose projections and IND-enabling safety submissions.
Multi-tracer and Co-injection Assessments
Sequential or dual-isotope imaging protocols that allow for the simultaneous evaluation of RDC distribution alongside metabolic or physiological markers. This approach correlates RDC performance with factors such as glycolysis, hypoxia, or proliferation within a single animal model.
Alfa Cytology's PET/CT imaging services for RDC preclinical development provide a full spectrum of solutions, from single‑time‑point biodistribution scans to dynamic pharmacokinetic studies with full kinetic modeling. The service portfolio includes custom radiolabeling, protocol design, image acquisition on state‑of‑the‑art preclinical systems, and quantitative analysis. For a detailed consultation or to request a project-specific proposal, please reach out to the technical team to discuss how these imaging capabilities can support your RDC pipeline.
References
For research use only. Not intended for any clinical use.
Alfa Cytology, a provider of RDC preclinical services, specializes in RDC design, conjugation, and analysis. Supported by a rich library of radionuclides, chelators, and linkers, we excel in targeting molecule design. We offer customized RDC services tailored to diverse requirements-your demand is our mission.
Copyright © 2026 Alfa Cytology. All rights reserved.